KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $135.1 million.

  • Travere Therapeutics' Total Current Liabilities fell 2892.26% to $135.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.1 million, marking a year-over-year decrease of 2892.26%. This contributed to the annual value of $200.8 million for FY2024, which is 1283.98% up from last year.
  • Latest data reveals that Travere Therapeutics reported Total Current Liabilities of $135.1 million as of Q3 2025, which was down 2892.26% from $189.5 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Total Current Liabilities high stood at $200.8 million for Q4 2024, and its period low was $85.0 million during Q1 2021.
  • Moreover, its 5-year median value for Total Current Liabilities was $135.1 million (2025), whereas its average is $142.8 million.
  • The largest annual percentage gain for Travere Therapeutics' Total Current Liabilities in the last 5 years was 5629.84% (2025), contrasted with its biggest fall of 2892.26% (2025).
  • Travere Therapeutics' Total Current Liabilities (Quarter) stood at $124.1 million in 2021, then increased by 14.57% to $142.2 million in 2022, then rose by 25.14% to $177.9 million in 2023, then increased by 12.84% to $200.8 million in 2024, then tumbled by 32.72% to $135.1 million in 2025.
  • Its Total Current Liabilities was $135.1 million in Q3 2025, compared to $189.5 million in Q2 2025 and $182.5 million in Q1 2025.